Geode Capital Management
IMVT icon

Geode Capital Management’s Immunovant IMVT Stock Holding History

Geode Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.1M Buy
2,234,602
+142,500
+7% +$4.34M ﹤0.01% 1302
2026
Q1 		$52M Buy
2,092,102
+234,570
+13% +$6.07M ﹤0.01% 1473
2025
Q4 		$47.2M Buy
1,857,532
+55,883
+3% +$1.25M ﹤0.01% 1515
2025
Q3 		$29M Sell
1,801,649
-23,953
-1% -$388K ﹤0.01% 1810
2025
Q2 		$29.2M Buy
1,825,602
+153,012
+9% +$2.31M ﹤0.01% 1750
2025
Q1 		$28.6M Buy
1,672,590
+157,570
+10% +$3.3M ﹤0.01% 1698
2024
Q4 		$37.5M Buy
1,515,020
+4,094
+0.3% +$116K ﹤0.01% 1613
2024
Q3 		$43.1M Buy
1,510,926
+96,924
+7% +$2.86M ﹤0.01% 1510
2024
Q2 		$37.3M Buy
1,414,002
+97,175
+7% +$2.76M ﹤0.01% 1552
2024
Q1 		$42.6M Buy
1,316,827
+43,861
+3% +$1.6M ﹤0.01% 1462
2023
Q4 		$53.6M Buy
1,272,966
+128,632
+11% +$4.73M 0.01% 1303
2023
Q3 		$43.9M Sell
1,144,334
-26,189
-2% -$592K 0.01% 1314
2023
Q2 		$22.2M Buy
1,170,523
+121,805
+12% +$2.27M ﹤0.01% 1783
2023
Q1 		$16.3M Buy
1,048,718
+45,123
+4% +$783K ﹤0.01% 1935
2022
Q4 		$17.8M Buy
1,003,595
+189,926
+23% +$2.39M ﹤0.01% 1847
2022
Q3 		$4.54M Buy
813,669
+18,697
+2% +$91.4K ﹤0.01% 2731
2022
Q2 		$3.1M Buy
794,972
+6,134
+0.8% +$26.5K ﹤0.01% 2955
2022
Q1 		$4.35M Sell
788,838
-31,561
-4% -$197K ﹤0.01% 2876
2021
Q4 		$6.99M Sell
820,399
-35,509
-4% -$293K ﹤0.01% 2690
2021
Q3 		$7.44M Buy
855,908
+8,798
+1% +$79.4K ﹤0.01% 2681
2021
Q2 		$8.95M Buy
847,110
+51,790
+7% +$723K ﹤0.01% 2532
2021
Q1 		$12.8M Buy
795,320
+40,830
+5% +$1.08M ﹤0.01% 2191
2020
Q4 		$34.8M Buy
754,490
+196,009
+35% +$9.06M 0.01% 1366
2020
Q3 		$19.7M Buy
558,481
+196,912
+54% +$5.92M ﹤0.01% 1546
2020
Q2 		$8.8M Buy
361,569
+342,394
+1,786% +$7.34M ﹤0.01% 1998
2020
Q1 		$298K Buy
+19,175
New +$288K ﹤0.01% 3430

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management's IMVT Position: Q2 2026 in Review

Geode Capital Management increased its Immunovant (IMVT) stake by 6.8% in Q2 2026, buying an estimated $4.34M and bringing the position to 2,234,602 shares worth $86.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1302.

Geode Capital Management first reported a position in IMVT in Q1 2020 and has held it in 26 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Geode Capital Management held 2,234,602 shares of Immunovant worth $86.1M as of Q2 2026.
  • Geode Capital Management bought 142,500 Immunovant shares in Q2 2026, an estimated $4.34M.
  • Immunovant made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1302 holding.
  • Geode Capital Management first reported a position in Immunovant in Q1 2020 and has held it in 26 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.